ORLANDO, FL, USA (UroToday.com) - Androgen deprivation therapy (ADT), the cornerstone of systemic therapy for men with prostate cancer at various stages of disease, is associated with a decline in bone mineral density and an increase in fracture risk. The National Comprehensive Cancer Network (NCCN) suggest that men at high risk of fracture and men treated with prolonged ADT should be treated with pharmacologic therapy to increase bone mineral density and reduce fracture risk.
Bone complications have been described using retrospective administrative database analyses and smaller prospective studies with relatively short follow-up, but they have not been reported using prospective cohorts with long term follow up.
We assessed the relationship of patient-reported bone health and ADT exposure using a population-based prospective cohort of prostate cancer survivors followed longitudinally from 15 years from diagnosis.....Click here to enlarge and view the poster
Listen to Alicia K. Morgans, MD speak about the study
Presented by Alicia K. Morgans,1 Kang-Hsien Fan,1, 2 Tatsuki Koyama,1, 2 Peter C. Albertsen,3 Michael Goodman,4 Ann S. Hamilton,5 Richard Hoffman,6 Janet L. Stanford,7 Antoinette M. Stroup,8 Christina L. Derleth,1 and David F. Penson1 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA
1Vanderbilt University School of Medicine, Nashville, TN 2Vanderbilt University Center for Quantitative Sciences and Department of Biostatistics, Nashville, TN 3University of Connecticut Health Center, Farmington, CT 4Emory University, Atlanta, GA 5University of Southern California, Los Angeles, CA 6University of New Mexico, Albuquerque, NM 7University of Washington, Seattle, WA 8University of Utah, Salt Lake City, UT
View Full 2013 GU Cancers Symposium Coverage
